EFMC
YMAB

Empire Financial Management Company’s Y-mAbs Therapeutics YMAB Stock Holding History

Empire Financial Management Company’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,000
Closed -$210K – 215
2024
Q3 		$210K Buy
+16,000
New +$203K 0.06% 203

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Empire Financial Management Company's YMAB Position: Q4 2024 in Review

Empire Financial Management Company sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 16,000 shares — an estimated $210K sold.

Empire Financial Management Company first reported a position in YMAB in Q3 2024 and held it in 1 quarter. The position peaked at $210K in Q3 2024. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Empire Financial Management Company reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Empire Financial Management Company sold 16,000 Y-mAbs Therapeutics shares in Q4 2024, an estimated $210K.
  • Empire Financial Management Company first reported a position in Y-mAbs Therapeutics in Q3 2024 and held it in 1 quarter.
  • Empire Financial Management Company's Y-mAbs Therapeutics position peaked at $210K in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Empire Financial Management Company's 13F filing for Q4 2024, filed 14 Feb 2025.